Chemotherapy-induced peripheral neuropathy — the numbness, tingling and burning pain that afflicts a large share of cancer patients on drugs like paclitaxel and cisplatin — has few effective preventive treatments. A new study from MD Anderson Cancer Center, published in the peer-reviewed journal Science, found that psilocybin — the psychoactive compound in "magic mushrooms" — prevented that nerve damage from developing in preclinical models, even across repeated chemotherapy cycles.
Preclinical, not yet proven in patients
The core finding needs an immediate caveat: this is a preclinical study conducted in mouse models, not a clinical trial in cancer patients, and its results — while peer-reviewed — do not by themselves establish that psilocybin will prevent nerve damage safely or effectively in humans. Researchers led by Moran Amit and Patrick Dougherty tested the approach against three commonly used chemotherapy drugs — cisplatin, paclitaxel and docetaxel — administered across multiple treatment cycles. As few as two doses of psilocybin given ahead of chemotherapy prevented cold hypersensitivity, protected sensory nerve endings, and preserved touch sensation in the animals, without blunting the chemotherapy's ability to kill tumor cells.
The proposed mechanism centers on mitochondria — the energy-producing structures inside nerve cells. Chemotherapy is known to deplete mitochondria in nerve fibers and disrupt their movement to where energy is needed, contributing to nerve injury. The researchers found that psilocybin, acting through serotonin 5-HT2A receptors, activates a signaling pathway that keeps mitochondria properly trafficked and nerve endings adequately fueled during chemotherapy exposure.
There is an urgent need for treatments that prevent nerve injury without interfering with lifesaving chemotherapy.
— Moran Amit, M.D., Ph.D., MD Anderson Cancer Center
Chemotherapy-induced peripheral neuropathy affects a substantial share of patients treated with common chemotherapy regimens and can persist long after treatment ends, sometimes forcing dose reductions or early discontinuation of otherwise effective cancer therapy. Existing options to prevent it are limited, which is part of why the preclinical results have generated interest — but translating an animal finding into a usable therapy is a long process, particularly for a federally controlled psychoactive substance with its own safety and regulatory complexities.
That translation is now beginning: the findings have supported a Phase 2 clinical trial, NeuroGuard, which is evaluating psilocybin against standard supportive care and placebo in patients undergoing chemotherapy for breast and colorectal cancers, among others. Only that human trial — not the mouse data alone — will show whether the protective effect holds up, at what dose, and with what safety profile in people already undergoing cancer treatment.
